既往接受过治疗的非小细胞肺癌患者接受纳武利尤单抗单药治疗后的假性进展
这项15中心回顾性队列研究纳入542例既往接受过治疗的晚期非小细胞肺癌患者,均接受纳武利尤单抗单药治疗。14例(3%)出现假性进展,其中多数在治疗3个月内出现缓解,假性进展患者的中位PFS1为1.0个月、PFS2为7.3个月。假性进展患者的中位PFS2显著短于典型缓解患者,但总生存显著长于典型进展患者。
要点
- 542例中14例(3%)出现假性进展,多数在纳武利尤单抗治疗3个月内出现缓解。
- 假性进展患者中位PFS1为1.0个月,中位PFS2为7.3个月。
- 假性进展患者中位PFS2显著短于典型缓解患者(p < 0.001)。
核心结论
- 假性进展不常见,出现假性进展的患者缓解持续时间短于典型缓解患者。
- 假性进展患者的生存获益明显优于典型进展患者。
- 需要进一步研究以阐明假性进展的特征和机制。
研究设计与样本
- 15中心回顾性队列研究。
- 纳入既往接受过治疗的晚期非小细胞肺癌患者542例,均接受纳武利尤单抗单药治疗。
- PFS1定义为至实体瘤疗效评价标准(RECIST)定义的首次进展时间,PFS2定义为至RECIST定义的第二次进展或死亡时间。
主要发现
- 542例患者中,20%显示典型缓解,53%显示进展,14例(3%)显示假性进展。
- 14例假性进展患者中多数(n = 10)在纳武利尤单抗治疗3个月内出现缓解。
- 假性进展患者中位PFS1为1.0个月,中位PFS2为7.3个月。
- 假性进展患者中位PFS2显著短于典型缓解患者的PFS(p < 0.001)。
- 假性进展患者总生存显著长于典型进展患者(p = 0.001)。
关键数值与推荐
- 假性进展定义为出现进展后经后续评估确认非真性进展(原文未给出具体判定标准)。
- RECIST定义的首次进展时间记为PFS1,第二次进展或死亡时间记为PFS2。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需要进一步研究以阐明假性进展的特征和机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Nivolumab is effective in the treatment of previously treated patients with advanced NSCLC. However, its radiological evaluation is challenging because of atypical patterns of response such as pseudoprogression. We examined the characteristics and outcomes of previously treated patients with NSCLC who were treated with nivolumab and experienced development of pseudoprogression. METHODS: We conducted a 15-center retrospective cohort study of previously treated patients with advanced NSCLC who received nivolumab monotherapy. For the patients who showed pseudoprogression, we defined progression-free survival 1 (PFS1) as the time to Response Evaluation Criteria in Solid Tumors-defined first progressive disease and progression-free survival 2 (PFS2) as the time to Response Evaluation Criteria in Solid Tumors-defined second progressive disease or death. RESULTS: Among the 542 patients included, 20% and 53% showed a typical response and progression, respectively. Of the 14 (3%) patients who showed pseudoprogression, most (n = 10) showed a response within 3 months of nivolumab treatment. The median PFS1 and PFS2 were 1.0 and 7.3 months, respectively. The median PFS2 was significantly shorter in the patients who showed pseudoprogression than the PFS of the patients with a typical response (p < 0.001). In contrast, patients showing pseudoprogression had significantly longer overall survival than did patients showing typical progression (p = 0.001). CONCLUSIONS: Pseudoprogression was uncommon, and the duration of response in patients who showed pseudoprogression was shorter than that in patients who showed a typical response. However, the survival benefit of pseudoprogression was markedly better than that of typical progression. Further research is required to elucidate the characteristics of and mechanisms underlying pseudoprogression.
引用
- Fujimoto D, Yoshioka H, Kataoka Y, et al. Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy. J Thorac Oncol. 2018. PMID: 30468872. doi:10.1016/j.jtho.2018.10.167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。